Promising safety profile: Early trials report tolerability comparable to incretin-based agents, though higher doses are associated with GI side effects (nausea, diarrhea, vomiting, constipation) Clinical Advantage over Others (Clinical Trial Evidence) Phase 2 obesity studies: At 48 weeks, retatrutide delivered weight reductions up to 24%, far exceeding results reported for monotherapy GLP-1 agents
When we know through decades of research and [from] obesity specialists saying that this is a chronic disease and it does need to be treated. Patients scramble for new solutions As a small business owner in Philadelphia, Rich Venezia buys his health insurance directly from IBX
Dominici MK, Le Blanc I, Mueller, et al
At the beginning and end of the 16-week study, the scientists measured three things: Taste sensitivity: Measured using strips infused with the four basic tastessweet, sour, salty, and bitter
Retatrutide is not currently positioned as a routine, commercially available prescription medication, which means there is no standardised pricing structure to reference
